How many drugs treat Heartburn?

Drug Landscape tracks 10 marketed treatments for Heartburn (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

What's the most recent regulatory action in Heartburn?

Most recent: Pepcid — FDA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/heartburn.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Heartburn — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Heartburn (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Heartburn, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Renacidin	MAGNESIUM CARBONATE	United Guardian	Vitamin C [EPC]		1990-01-01
Pepcid	famotidine	Generic (originally Yamanouchi/Merck)	Histamine-2 Receptor Antagonist [EPC]	Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Solute carrier family 22 member 2	1986-10-01
Zantac	ranitidine	GSK (originally Glaxo)	H2 receptor antagonist	Multidrug and toxin extrusion protein 1, Acetylcholinesterase, Histamine H2 receptor	1983-06-01
Gaviscon	MAGNESIUM SILICATE	Sanofi	magnesium silicate		1983-01-01
Gaviscon	ALGELDRATE	Sanofi	algeldrate		1983-01-01
Bss	SODIUM CITRATE	B Braun	sodium citrate	Calcium	1980-01-01
Milk of Magnesia	magnesium hydroxide	Generic (multiple manufacturers)	Osmotic laxative, Antacid	Gastric acid (direct neutralization) + osmotic effect in intestine	1880-01-01
Potassium Alum	Alum	Novartis Pharmaceuticals	Non-Standardized Plant Allergenic Extract [EPC]
Ultra Strength Antacid	PEPPERMINT	Target Corporation
Alka-Seltzer Gold	GOLD	Bayer HealthCare LLC.

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-05-12 — Pepcid · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 4 drugs in Heartburn
Sanofi · 2 drugs in Heartburn
Bayer HealthCare LLC. · 1 drug in Heartburn
GSK (originally Glaxo) · 1 drug in Heartburn
Generic (multiple manufacturers) · 1 drug in Heartburn
Generic (originally Yamanouchi/Merck) · 1 drug in Heartburn
Novartis Pharmaceuticals · 1 drug in Heartburn
Target Corporation · 1 drug in Heartburn
United Guardian · 1 drug in Heartburn
B Braun · 1 drug in Heartburn

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Heartburn:

Cite this brief

Drug Landscape (2026). Heartburn — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/heartburn. Accessed 2026-06-10.

Heartburn full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing